[rHuGM-CSF: a possible therapeutic treatment in resistant chronic wound healing: our first observations].
Skin wounds are exposed to a complex series of events that usually culminate in wound healing. This process is well known in relation to histological events, although mechanisms that underlie its regulation remain unclear at a molecular level; not only tissue growth factors but also a number of cytokines are involved. In this paper we report our experience in two cases about the treatment of resistant chronic ulcers of lower limbs using GM-CSF human recombinant: rHuGM-CSF as a topic treatment over 8 weeks. The results consist in a complete healing in one patient and in excellent improvement in the other one. Accordingly, we realized the idea that GM-CSF could be included between compounds able in promoting healing, in relation to direct or indirect effects in relation of its topical GM-CSF use. However, further study will be needed to determine dosage, method of application and type of recombinant material to be used for best results.
Castrogiovanni
P
P
Dipartimento di Anatomia, Patologia Diagnostica, Medicina Legale, Igiene e Sanità Pubblica G.F. Ingrassia, Università di Catania, Italia. pacastro@unict.it
Ventimiglia
P
P
Imbesi
R
R
D000368:Aged; D002908:Chronic Disease; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011994:Recombinant Proteins; D012883:Skin Ulcer / Q000188:drug therapy*; D014945:Wound Healing
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor